New drug cocktail targets Hard-to-Treat cancers in early trial

NCT ID NCT03454035

Recruiting now Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase study tests two drugs—ulixertinib and palbociclib—together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find a safe dose and check for side effects. About 45 adults whose cancers have not responded to standard treatments will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ulixertinib (BVD-523) and palbociclib (Ibrance)
What this could lead to: If successful, this could point toward a new treatment option for advanced pancreatic cancer and certain melanomas that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial with only 45 participants, focused on safety and dosing. It is too soon to know if the combination will be effective, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm melanoma metastatic melanoma neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA PANCREATIC CANCER TUMOR, SOLID

Contacts and locations

Locations

Lineberger Comprehensive Cancer Center
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.